drugset
drugset / Trial / NCT04447235

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

NCT04447235 ↗

Phase 2 Terminated 77 enrolled Cancer Institute of the State of São Paulo
RandomizedParallel-groupDouble-blindTreatment

Summary

Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19

Timeline

Start
2020-07-23
Primary completion
2022-06-30
Completion
2022-06-30

Outcome

Outcome not reported

Stopped: “futility analysis has demonstrated no difference between arms”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 12 mg —
Subject Losartan Other / unclassified 50 mg Oral

Indications

COVID-19 cancer